Stockscreener 앱 받기
11.33
2.24%
-0.26
시간 외 거래:
11.46
0.13
+1.15%
전일 마감가:
$11.59
열려 있는:
$11.7
하루 거래량:
1.44M
Relative Volume:
1.35
시가총액:
$899.94M
수익:
$175.11M
순이익/손실:
$-221.25M
주가수익비율:
-3.7129
EPS:
-3.0515
순현금흐름:
$-167.00M
1주 성능:
-12.03%
1개월 성능:
+7.09%
6개월 성능:
-16.32%
1년 성능:
+173.01%
1일 변동 폭
$11.08
$11.81
1주일 범위
$11.08
$13.18
52주 변동 폭
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.33 | 920.60M | 175.11M | -221.25M | -167.00M | -3.0515 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-12-12 | 개시 | Raymond James | Strong Buy |
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN
Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet - MSN
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN
HC Wainwright & Co. Maintains Phathom Pharmaceuticals (PHAT) Buy Recommendation - MSN
Phathom Pharmaceuticals brings senior marketing leader to ThinkDHC patient engagement event - Traders Union
Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday - MarketBeat
PHAT (Phathom Pharmaceuticals Inc.) reports narrower than expected Q4 2025 loss, pushing shares up 4.6 percent in today’s trading.Market Buzz Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
(PHAT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
PHAT (Phathom Pharmaceuticals Inc.) posts narrower than expected Q4 2025 loss, shares rise modestly in today’s regular trading.Earnings Quality - Cổng thông tin điện tử Tỉnh Sơn La
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8%Time to Sell? - MarketBeat
Phathom Pharmaceuticals (PHAT) Stock: Suitable for Investors? (+1.97%) 2026-04-20Trend Following - Cổng thông tin điện tử tỉnh Lào Cai
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 - The Manila Times
Phathom to pair Q1 results with a business update in April 30 webcast - Stock Titan
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business ... - Caledonian Record
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return - Yahoo Finance
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
Phathom Pharmaceuticals (PHAT) Stock Analysis: A Potential 85% Upside Awaits Investors - DirectorsTalk Interviews
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Responsive Playbooks and the PHAT Inflection - Stock Traders Daily
PHAT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug Highlights: Is Phathom Pharmaceuticals Inc a cyclical or defensive stock2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
[ARS] Phathom Pharmaceuticals, Inc. SEC Filing - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) sets 2026 virtual meeting, director elections and say-on-pay vote - Stock Titan
Quarterly Recap: How correlated is Phathom Pharmaceuticals Inc to the S P5002026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Portfolio Recap: Is Phathom Pharmaceuticals Inc a cyclical or defensive stockQuarterly Profit Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
PHAT Technical Analysis & Stock Price Forecast - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
Portfolio Recap: What are the risks of holding Phathom Pharmaceuticals IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) Stock News & Articles - 247wallst.com
Phathom upgraded at Barclays following pullback, Voquezna optimism ) - Seeking Alpha
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Analyst Upgrade - MarketBeat
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - Benzinga
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
Barclays Upgrades Phathom Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $18 From $16 - MarketScreener
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook - investing.com
Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Weekly Recap: Does Phathom Pharmaceuticals Inc offer margin of safetyTrade Performance Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):